Bovidip

Main information

  • Trade name:
  • Bovidip 2% w/v Concentrate for Teat Dip or Spray Solution
  • Pharmaceutical form:
  • Teat dip concentrate
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Bovidip 2% w/v Concentrate for Teat Dip or Spray Solution
    Ireland
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • Tars
  • Therapeutic area:
  • Cattle Females

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0331/001
  • Authorization date:
  • 07-01-2011
  • EU code:
  • UK/V/0331/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Revised:November2012

AN.01679/2011

Page1of5

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Bovidip2%w/vConcentrateforTeatDiporSpraySolution

forcows.

2 QUALITATIVEANDQUANTITATIVECOMPOSITION

Activesubstance:iodine,2%w/v

2gper100mlasavailableiodine(concentrate).

25mgper5mldoseasavailableiodine(ready-to-use

solution).

Excipients

Emollients: glycerol,10%w/v

Forafulllistofexcipients,seesection6.1

3. PHARMACEUTICALFORM

ConcentrateforTeatDiporSpraySolution.

ClearBrownLiquid.

4. CLINICALPARTICULARS

4.1 Targetspecies

Bovine.

4.2 Indicationsforuse,specifyingthetargetspecies

Teatdisinfectionasanaidinthepreventionofmastitisinlactatingdairycows.

4.3 Contra-indications

Donotuseincasesofknownhypersensitivitytoiodine,ortoanyofthe

excipients.

Donotmixwithotherchemicals.

4.4 Specialwarningsforeachtargetspecies

Priortomilking,washteatswithanudderwashsolutionanddrywitha

disposablepapertowel.

Discardanyproductthatbecomescontaminated.

Revised:November2012

AN.01679/2011

Page2of5

4.5 Specialprecautionsforuse

i)Specialprecautionsforuseinanimals

Allowproducttodrybeforeexposingthecowstowet(rainy),coldorwindy

conditions.

Useininjuredteatsmaydelaythewound-healingprocess.Itis

recommendedthattreatmentbediscontinueduntilteatlesionshave

resolved.

Ifsignsofdiseasepersistorappear,consultaveterinarysurgeon.

ii)Specialprecautionsforthepersonadministeringtheveterinarymedicinal

producttoanimals

Careshouldbetakenavoideyecontact.Incaseofeyecontact,flushthe

eyeswithcopiousamountsofwaterandseekmedicaladvice.

Incaseofingestion,drinklargequantitiesofwaterandobtainmedical

attentionassoonaspossible.

Whenusedasspray,avoidworkinginspraymist.

Washhandsafteruse.

Personswithiodineallergyshouldwearglovesandmask.

iii)Otherprecautions

None.

4.6 Adversereactions

Noneknown.

4.7. Useduringpregnancy,lactationorlay

Indicatedforuseduringpregnancyandlactation.

4.8.Interactionwithothermedicinalproductsandotherformsofinteraction

Theuseofthisproductinthespecifiedmanner(topicalantiseptic)hasno

knowninteractionswithothermedicamentsornutrition.

4.9.Amountstobeadministeredandadministrationroute

Dilutebeforeuse.Prepareafreshsolutiondaily.DiluteonepartofBovidip2%

w/vConcentrateforTeatDiporSpraySolutionwiththreepartsofcleanwater

andmixwell.Alwayscleanthedipcuporspraycontainerafteruse.

Amountstobeadministered:about5mlpercowperapplication.

Administrationroute:

oDipping:Dipeachteatimmediatelyaftermilkinginateatdipcup

containingdilutedproduct.Dipthefulllengthoftheteatsandreplenish

thedipcupasnecessary.

oSpraying:Spraytheentiresurfaceoftheteatsaftereachmilking.

Revised:November2012

AN.01679/2011

Page3of5

4.10.Overdose

Notapplicable.Theproductisfortopicalapplication.Significantabsorption

doesnotoccur.

4.11.Withdrawalperiods

Meat:Zerodays.

Milk:Zerohours.

5. PHARMACOLOGICALPROPERTIES

PharmacotherapeuticGroup:Productsforteatsandudders:Disinfectants

ATCVetCode:QG52A

5.1.Pharmacodynamicproperties

Iodinesolutionsreactwiththeorganicmatterofbacteriaandvirusestorender

themharmless.Themechanismofkillappearstobeduetoanoxidative-

reductivereaction,involvingvariouscellwallconstituents,whichare

irreversiblytransformed.Thesulphydryllinkages,inbacterialcellwall

components,arespecificallytargetedbyiodine.

Bovidip2%w/vConcentrateforTeatDiporSpraySolutionisbactericidal(EN

1040andEN1656)against:

Pseudomonasaeruginosa

Staphylococcusaureus

Enterococcushirae

Proteusvulgaris

5.2. Pharmacokineticparticulars

Literaturesuggeststhatabsorptionofiodinethroughtheskiniswellbelow

levelswhichwouldleadtopharmacokineticactivityinthebody.

6. PHARMACEUTICALPARTICULARS

6.1. Listofexcipients

WaterPurified

Glycerol

Macrogollaurylether

Poloxamer

Sodiumiodide

Citricacidmonohydrate

Sodiumhydroxide

Revised:November2012

AN.01679/2011

Page4of5

6.2.Incompatibilities

Intheabsenceofcompatibilitystudies,thisveterinarymedicinalproductmust

notbemixedwithotherveterinarymedicinalproducts.

6.3.Shelflife

Shelflifeoftheveterinarymedicinalproductaspackagedforsale:18months.

Shelflifeafterfirstopeningtheimmediatepackaging:6months.

Shelflifeafterdilutionaccordingtodirections:1day.

6.4.Specialprecautionsforstorage

Storeuprightinthetightlyclosedoriginalcontainer.

Donotstoreabove25°C.

Protectfromfrost.

Iftheproducthasfrozen,thawinawarmplaceandshakewellbeforeuse.For

thelargerpacksizes,theproductshouldberolledsufficientlytomixthe

solution.Undernocircumstancesshouldanattemptbemadetoshakethe60

or200litrepacks.

Protectfromlight.

6.5.Natureandcompositionofimmediatepackaging

High-densitypolyethylene5,10,20,60or200litrecansclosedwithhigh-

densitypolyethylenescrewcaps,securedwithasealingring.

The200litrecontainershouldnotbereturnedforre-filling.

Notallpacksizesmaybemarketed.

6.6.Specialprecautionsforthedisposalofunusedveterinarymedicinal

productsorwastematerialsderivedfromtheuseofsuchproducts,if

appropriate

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductsshouldbedisposedofinaccordancewithlocal

requirements.

7. MARKETINGAUTHORISATIONHOLDER

DeLavalInternationalAb

Industriepark-Drongen10

B-9031Gent

Belgium

8. MARKETINGAUTHORISATIONNUMBERS

UK: Vm17140/4008

Ireland: 10827/003/001

Revised:November2012

AN.01679/2011

Page5of5

9. DATEOFTHEFIRSTAUTHORISATION

09July2007

10. DATEOFREVISIONOFTHETEXT

November2012

17-10-2018

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Published on: Tue, 16 Oct 2018 00:00:00 +0200 The duration of the vaccination campaign sufficient to eliminate lumpy skin disease (LSD) mainly depends on the vaccination effectiveness and coverage achieved. By using a spread epidemiological model, assuming a vaccination effectiveness of 65%, with 50% and 90% coverage, 3 and 4 years campaigns, respectively, are needed to eliminate LSD. When vaccination effectiveness is 80% to 95%, 2 years of vaccination at coverage of 90% is sufficient to eliminate LSD vir...

Europe - EFSA - European Food Safety Authority Publications

7-8-2018

Seaweed consumption: remain vigilant to the risk of excess iodine intake

Seaweed consumption: remain vigilant to the risk of excess iodine intake

Over the last few years, seaweed has become increasingly common on our plates. Fresh, dried or as a food supplement, its iodine content varies and can sometimes be high. ANSES assessed the risk of excess iodine intake from the consumption of seaweed-based products. In view of the non-negligible risk of exceeding the upper limit of safe intake for iodine, the Agency advises against the consumption of seaweed and seaweed-based food supplements by certain at-risk populations, and recommends that regular con...

France - Agence Nationale du Médicament Vétérinaire

12-6-2018

Dave’s Pet Food Voluntarily Recalls 95% Premium Beef Canned Dog Food Due to Potentially Elevated Levels of Thyroid Hormone

Dave’s Pet Food Voluntarily Recalls 95% Premium Beef Canned Dog Food Due to Potentially Elevated Levels of Thyroid Hormone

Dave’s Pet Food of Agawam, MA is recalling a single lot of Dave’s Dog Food 95% premium beef cans because the products potentially contain elevated levels of beef thyroid hormone.

FDA - U.S. Food and Drug Administration

23-5-2018

95% Ethyl Alcohol Product by Ethanol Extraction: Recall - Due to a Possible Contamination with Methanol

95% Ethyl Alcohol Product by Ethanol Extraction: Recall - Due to a Possible Contamination with Methanol

Methanol,a highly toxic type of alcohol, can cause serious and sometimes fatal damage if ingested by humans or animals.

FDA - U.S. Food and Drug Administration

23-5-2018

Ethanol Extraction Recalls Alcohol Product Because of Possible Health Risk

Ethanol Extraction Recalls Alcohol Product Because of Possible Health Risk

Lake Michigan Distilling Company, LLC of La Porte, Indiana, doing business as Ethanol Extraction, is recalling its 95% Ethyl Alcohol product (“Product”) because of possible contamination with methanol, a highly toxic type of alcohol that can cause serious and sometimes fatal damage if ingested by humans or animals.

FDA - U.S. Food and Drug Administration

21-10-2018

The MQSA was intended to address mammography quality concerns and it’s been a huge success. Image quality has improved, radiation dose has declined and equipment violations have all but disappeared. Today the 5-year breast cancer survival rate is 95%-99%,

The MQSA was intended to address mammography quality concerns and it’s been a huge success. Image quality has improved, radiation dose has declined and equipment violations have all but disappeared. Today the 5-year breast cancer survival rate is 95%-99%,

The MQSA was intended to address mammography quality concerns and it’s been a huge success. Image quality has improved, radiation dose has declined and equipment violations have all but disappeared. Today the 5-year breast cancer survival rate is 95%-99%, up from 84% in 1995.

FDA - U.S. Food and Drug Administration

1-8-2018

Lyrica (Pfizer Europe MA EEIG)

Lyrica (Pfizer Europe MA EEIG)

Lyrica (Active substance: pregabalin) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5223 of Wed, 01 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/546/T/95

Europe -DG Health and Food Safety

13-6-2018

Scientific guideline:  Concept paper on preparation of a revised guideline on the evaluation of medicinal products indicated for treatment of bacterial infections, draft: consultation open

Scientific guideline: Concept paper on preparation of a revised guideline on the evaluation of medicinal products indicated for treatment of bacterial infections, draft: consultation open

This concept paper proposes the development of a single guideline on the clinical evaluation of medicinal products indicated for treatment of bacterial infections. The development of this single guideline is intended to merge, revise and add to the guidance that is currently included in two separate documents as follows: guideline on the evaluation of medicinal products indicated for treatment of bacterial infections (CPMP/EWP/558/95 Rev. 2), adopted in 2011 and in force since 2012 and the addendum ...

Europe - EMA - European Medicines Agency

8-5-2018

Child-resistant packaging requirements for medicines - Guidance on TGO 95

Child-resistant packaging requirements for medicines - Guidance on TGO 95

New guidance document published to assist medicine sponsors in meeting the requirements for child-resistant packaging (TGO 95)

Therapeutic Goods Administration - Australia